Peer-reviewed article
Insights into Physician's Perceptions of Levocloperastine's Safety and Efficacy in Children: An Online Survey in Clinical Practice
Dr Krishna Deepak Sathiraju ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This is a survey of Indian physicians' opinions about levocloperastine, a cough medicine for children aged 2-15 years. The doctors reported high confidence in the drug's safety and effectiveness, with most saying it works quickly and causes few side effects. However, this document is about physician perceptions rather than actual child health outcomes or well-being.
Key points
- 86.6% of surveyed physicians prescribed levocloperastine to children in clinical practice
- 69.6% of physicians reported it was faster-acting than traditional cough medicines
- 96.9% of physicians found it well-tolerated in pediatric patients
- 80.7% reported reduced night-time sleep disruptions
Limitations
This is a survey of physician opinions only, not an evaluation of actual health outcomes or impact on children's well-being. It does not measure whether children actually improved, recovered faster, or experienced any harms.
Abstract
Cough is a common symptom in pediatric patients, often requiring effective and well-tolerated antitussive treatments.Although traditional agents like dextromethorphan and codeine are effective, they are associated with side effects likedrowsiness, nausea, and dependency risks. Levocloperastine (LCP), a nonopioid antitussive, has emerged as a safer alternativewith a dual mechanism of action targeting both central and peripheral pathways. This manuscript highlights the findings froman online survey that gathered insights from Indian physicians regarding their perceptions of LCP's safety and efficacy inchildren aged 2 to 15 years. The survey data came from 161 physicians through a structured electronic questionnaire. Resultsindicated high physician confidence in LCP's rapid onset of action, tolerability, and minimal side effects. Notably, 86.6%of participants prescribed LCP in their clinical practice to the children, with 69.6% finding it faster-acting than traditionalagents. Additionally, 80.7% reported reduced night-time sleep disruptions, and 96.9% found it well-tolerated in pediatricpatients. These findings align with existing literature and reinforce LCP's role as a preferred antitussive in pediatric coughmanagement.